Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
TP53BP2 encodes a member of the ASPP (apoptosis-stimulating protein of p53) family of p53 interacting proteins. Additionally we are shipping Tumor Protein P53 Binding Protein 2 Proteins (3) and Tumor Protein P53 Binding Protein 2 Kits (2) and many more products for this protein.
Showing 10 out of 71 products:
Human Monoclonal TP53BP2 Primary Antibody for IF, WB - ABIN968491
Iwabuchi, Li, Massa, Trask, Date, Fields: Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2. in The Journal of biological chemistry 1998
Show all 3 Pubmed References
Human Polyclonal TP53BP2 Primary Antibody for IF (p), IHC (p) - ABIN674394
Xie, Yang, Chi, Yang, Wang, Xu: Prognostic values of apoptosis-stimulating P53-binding protein 1 and 2 and their relationships with clinical characteristics of esophageal squamous cell carcinoma patients: a retrospective study. in Chinese journal of cancer 2017
Human Polyclonal TP53BP2 Primary Antibody for IHC, ELISA - ABIN1584022
Matsumoto, Weckbecker, Cory: Antineoplastic effect of the combination of 2,3-dihydro-1H-pyrazole[2,3a]imidazole plus deoxyadenosine/erythro-9-(2-hydroxyl-3-nonyl)adenine in mice with L1210 leukemia cells. in Cancer communications 1990
Show all 2 Pubmed References
These findings uncover a novel role of Aspp2 in regulating vertebrate embryonic growth.
These findings identify TP53BP2 as a strong candidate causative gene for central nervous system (CNS) defects in 1q41q42 microdeletion syndrome.
SPP2 dominates the biological outcome, thus switching from a Gal-1 supported growth-promoting setting to a senescence inducing and stemness suppressive program in cancer cells. Our results support Ras nanocluster as major integrators of tumour fate decision events.
After genotoxic stress, Aspp1 (show PPP1R13B Antibodies) promotes hematopoietic stem cell (HSC (show FUT1 Antibodies)) cycling and induces p53 (show TP53 Antibodies)-dependent apoptosis in cells with persistent DNA damage foci. Aspp1 (show PPP1R13B Antibodies) also attenuates HSC (show FUT1 Antibodies) self-renewal and accumulation of DNA damage in p53 (show TP53 Antibodies) null HSCs.
ASPP2 may participate in the lipid metabolism of non-alcoholic steatohepatitis and attenuate liver failure.
ASPP2 prevents beta-catenin (show CTNNB1 Antibodies) from transactivating ZEB1 (show ZEB1 Antibodies) directly by forming an ASPP2-beta-catenin (show CTNNB1 Antibodies)-E-cadherin (show CDH1 Antibodies) ternary complex
findings suggest that the identified STAT1 (show STAT1 Antibodies)/ASPP2 pathway may connect tumor suppression and cell polarity to neuroinflammation
our studies demonstrate the role of Siah2 (show SIAH2 Antibodies) in regulation of tight junction integrity and cell polarity under hypoxia, through its regulation of ASPP2 stability.
ASPP2 is a tumor suppressor that suppresses squamous cell carcinoma via inflammatory signaling through NF-kappaB (show NFKB1 Antibodies)-mediated repression of p63 (show CKAP4 Antibodies).
Our study demonstrates a novel role for ASPP1 (show PPP1R13B Antibodies) and ASPP2 in the death of retinal ganglion cells.
regulates epithelial cell polarity in cooperation with PAR-3 (show F2RL2 Antibodies) to form an active PAR (show AFG3L2 Antibodies) complex
Results showed that protein expression levels of ASPP2 and P53 (show TP53 Antibodies) were significantly higher in esophageal squamous cell carcinoma tissues than in paired noncancerous tissues.
Expression levels of TP53BP2, FBXO28 (show FBXO28 Antibodies), and FAM53A (show Fam53a Antibodies) genes were associated with patient survival specifically in ER-positive, TP53 (show TP53 Antibodies)-mutated tumors.
These data together implicated a critical impact of MiR (show MLXIP Antibodies)-205/ASPP2 on promoting epithelial-mesenchymal transition.
ASPP2 is a key regulator of BECN1 (show BECN1 Antibodies)-dependent autophagy.
ASPP2 suppresses invasion, peritoneal dissemination and TGF-beta1 (show TGFB1 Antibodies)-induced EMT (show ITK Antibodies) by inhibiting Smad7 (show SMAD7 Antibodies) degradation mediated by ITCH in gastric cancer cells.
Our results suggest that Gal-1 and ASPP2 functionally compete in nanocluster for active Ras on the plasma membrane. ASPP2 dominates the biological outcome, thus switching from a Gal-1 supported growth-promoting setting to a senescence inducing and stemness suppressive program in cancer cells. Our results support Ras nanocluster as major integrators of tumour fate decision events.
ASPP2 suppresses p53 (show TP53 Antibodies) target gene transactivation, promoter occupancy, and endogenous p53 (show TP53 Antibodies) target gene expression in response to DNA damage
In this study, in recombinant adenovirus-ASPP2-infected HepG2 cells, ASPP2 overexpression induces amphiregulin (show AREG Antibodies) expression in a p53 (show TP53 Antibodies)-dependent manner
Downregulated expression of ASPP2 is associated with hepatocellular carcinoma.
This gene encodes a member of the ASPP (apoptosis-stimulating protein of p53) family of p53 interacting proteins. The protein contains four ankyrin repeats and an SH3 domain involved in protein-protein interactions. It is localized to the perinuclear region of the cytoplasm, and regulates apoptosis and cell growth through interactions with other regulatory molecules including members of the p53 family. Multiple transcript variants encoding different isoforms have been found for this gene.
tumor protein p53 binding protein, 2
, apoptosis-stimulating of p53 protein 2-like
, apoptosis-stimulating of p53 protein 1
, protein phosphatase 1 regulatory subunit 13B
, transformation related protein 53 binding protein 2
, tumor protein p53-binding protein, 2
, apoptosis-stimulating of p53 protein 2
, p53-binding protein 2
, tumor suppressor p53-binding protein 2
, BCL2-binding protein
, apoptosis-stimulating protein of p53, 2
, renal carcinoma antigen NY-REN-51